J. Enzyme Inhibition, 1989, Vol. 3, pp. 49-56 Reprints available directly from the publisher Photocopying permitted by license only

cDNA CLONING OF HUMAN CALPASTATIN: SEQUENCE HOMOLOGY AMONG HUMAN, PIG, AND RABBIT CALPASTATINS

KIYOZO ASADA,* YOSHIZUMI ISHINO, MASAMITSU SHIMADA, TOMOKO SHIMOJO, MASAHIRO ENDO, FUSAO KIMIZUKA, IKUNOSHIN KATO, MASATOSHI MAKI,¹ MASAKAZU HATANAKA,¹ and TAKASHI MURACHI[§]

Pharmaceutical Research Laboratories, Takara Shuzo Co., Ltd., Kyoto 600-91, Japan, and ¹Institute for Virus Research and § Department of Clinical Science and Laboratory Medicine, Faculty of Medicine, Kyoto University, Kyoto 606, Japan

(Received 11 October, 1988)

cDNA of human calpastatin, an inhibitor protein specific for calpain (EC 3.4.22.17; Ca^{2+} -dependent cysteine proteinase) was isolated by screening of a library prepared from human liver mRNA with pig calpastatin cDNA fragment as a probe. The primary structure of human calpastatin was deduced from the nucleotide sequence of the cDNA and compared with that of pig and rabbit calpastatins already reported. Human calpastatin consisted of 673 amino acid residues and had 78% and 77% indentity to pig or rabbit calpastatins. respectively. Human calpastatin had a domain structure with four internally repetitive sequences and one N-terminal non-homologous sequence like the other calpastatins. Human calpastatin had two deletions, 22 and 13 residues long in domain L and domain 1, respectively, compared to pig or rabbit calpastatins.

KEY WORDS: Proteinase inhibitor, library screening, nucleotide sequence, predicted amino acid sequence.

INTRODUCTION

Calpastatin is an endogenous protein inhibitor acting specifically on calpain (EC 3.4.22.17; Ca^{2+} -dependent cysteine proteinase).¹ Both calpain and calpastatin are widely distributed in mammalian and avian cells.^{2.3} The physiological roles of calpain have not been clarified, but this proteinase-proteinase inhibitor system may be important in various cellular functions, coupled with calcium ion mobilization.⁴⁻⁹

The primary structure of pig calpastatin has been identified by nucleotide sequencing of cloned cDNAs and by Edman degradation of the inhibitor purified from pig heart. The inhibitor is composed of 713 amino acid residues, and contains four internally repetitive sequences (domains 1-4) and one non-homologous sequence on the amino-terminal side (domain L), each separated by about 140 amino acid residues.^{10,11} This structural feature is similar to that of rabbit calpastatin.¹²

Each repetitive region, domains 1-4, inhibited both calpain I (low-Ca²⁺-requiring form) and calpain II (high-Ca²⁺-requiring form) and each structural domain was a functional unit of calpastatin.^{13,14} The structure-function relationship for pig calpas-



^{*}Correspondence.

K. ASADA ET AL.

tatin has been studied by functional analysis of various deletion mutants of domain 3.¹⁵ The central region, composed of 52 amino acid residues (spanning 441 to 492 bp by our coordinates) seems to be an important region for the function of the inhibitor. We have proposed that there is a central consensus sequence of 12 amino residues in each domain, which is essential for the formation of the tertiary structure. A similar kind of analysis also has been reported for rabbit calpastatin¹⁶ and a peptide of 34 residues long in the central region of domain 1 inhibits both kinds of calpains.¹⁷

To find if human calpastatin has structural features similar to those for pig and rabbit calpastatins,^{11,12} we cloned human calpastatin cDNA and compared its primary structure deduced from the cDNA nucleotide sequence with those of different mammalian sources.

MATERIALS

The cDNA library and poly(A+) mRNA were purchased from Clontech Inc. (Palo Alto, CA, USA). Reverse transcriptase, DNA polymerase I, RNase H, T4 DNA ligase, methylase, and restriction enzymes were the products of Takara Shuzo Co., Ltd. (Kyoto, Japan); oligonucleotides were prepared at the same company. Nylon membrane was purchased from Amersham (UK). λ gt 10 DNA and packaging components were obtained from Stratagene (San Diego, CA, USA).

METHODS

Construction of cDNA Library

Double-stranded cDNA was synthesized from $1-8 \mu g$ of human liver poly(A+) RNA as described by Gubler and Hoffman¹⁸ except that $0.3-1.2 \mu g$ of random hexanucleotide was used as the primer. cDNA was then treated with *Eco*RI methylase, ligated with *Eco*RI linker, and digested with *Eco*RI. Linker-attached cDNA was gel-filtered with Sepharose CL-4B and ligated with *Eco*RI-digested phage vector λgt 10; the ligation mixture was packaged *in vitro* as described by Huynh *et al.*¹⁹

Screening of cDNA Library

About 2×10^4 phages were spread on a square plate (10 \times 10 cm) and transferred to a nylon membrane. Hybridization was performed overnight at 65°C in a solution containing 6 \times SSC (1 \times SSC was 0.15 M NaCl/0.15 M sodium citrate, pH 7.0), 1% SDS, 100 µg/ml heat-denatured salmon sperm DNA, 5 \times Denhardt's (1 \times Denhardt's was 0.02% bovine serum albumin/0.02% polyvinylpyrrolidone/0.02% Ficoll), and ³²P-labelled probe DNA at 10⁶ cpm/ml. Filters were washed four times for 15 min each time in 2 \times SSC and 0.1% SDS at room temperature. Excess liquid was drained off the filters, which were autoradiographed at -70° C with an intensifying screen.

Nucleotide Sequencing

Nucleotides were sequenced as described by Messing.²⁰ Restriction fragments of cDNA were subcloned into M13 mp 18/19 and single-stranded DNA was prepared. Chain termination reactions were carried out with a kit prepared by Takara Shuzo.

HUMAN CALPASTATIN

Homology Search

A program DNASIS developed in Hitachi Software Engineering Co., Ltd. (Yokohama, Japan) was employed for dot matrix analysis and a best fit alignment of two similar sequences.

RESULTS

cDNA Cloning of Human Calpastatin

A commercial cDNA library constructed from human liver mRNA with a phage vector λ -gt 11 was screened for human calpastatin cDNA clones. The 935-bp *Pst*I fragment of pCSFL713, spanning the region of domain 1 to domain 2 in pig calpastatin (Takano *et al.*),¹¹ was used as a probe. In all, 51 candidate clones were obtained from 10⁵ recombinant phages, and eight clones arbitrarily selected were found to have an insertion fragment of the same size, 1.8 kb. One of these clones, designated λ cs 19, was used to sequence the nucleotides of the insertion fragment.

Another clone was obtained that covered the 5'-terminal region of the cDNA that $\lambda cs 19$ lacked. In this screening, the desired clones were isolated from the cDNA library constructed with random hexanucleotide primers with the ³²P-labelled *Eco*RI-*AccI* probe fragment or $\lambda cs 19$ (shown in Figure 1). Four candidate clones were isolated from the recombinant phages and one of these clones, designated $\lambda cs 143$, covered the 5'-terminal region of the cDNA shown in Figure 1.




FIGURE 1 Restriction map of cDNA clones of human calpastatin and sequencing strategy. The human calpastatin coding region is indicated by the solid box. Coordinates are given as the nucleotide base number (bp) starting from the 5'-terminal end. Negative numbers are used for the 5' untranslated regions. Open boxes under the restriction map show the regions two clones (λ cs 19 and λ cs 143) cover. Arrows below each clone show the direction of sequencing and the region sequenced.



	cttgg	-90 9009	iceg.	tcas	itct	cca		ctat		60 toge	saca	acct	cago		-000	tato	-3 agc1		tct	:001	ata	acc	a00		teti	tci
±1	+3	30							+6	0			•					,			•••		- 3 -			
ATGAATCOCACAGAAACCAAGGC	TGTAN	ALC:	AGA	ACCT	GAG	VAGA	GTC	-	TCAAC	ČAAC	CTG	TCTG	TGGT	TCAT	GAG		ATC	E M	GAA	GG/	MG	CC.A		GAN	AC/	
мнртетка	V K	Ť	ε	٩	E M	к	s	Q :	sτ	κ	LS	5 V	v	н	εł	ĸ	ş	Q.	Ε	G	ĸ	Ρ	ĸ	E)	1 1	ŗ
	10																30									
CAAAAAAGCCTACCCAAGCAGGC	ATCAGA		-	AAG1			-	-	+18		CTT	·~~•	-		-		~~.		~ • •							1
PKSLPKQA	S D	T	G	s	ĸ) A	н	N	к к	*	v s	R	S	A	E (0	P	s	bANG F	***	s	GCA	GAA F			NC1 r
	5 8															•	70	•	-				-		• •	
CCACAAGACACGGTTTCTGCTGG	TIGGAGA		TGT	тост	nom	TOP	- T ICC		+30			стc					~ • • •			~~~	~.		~~~	~~ ~ ~		. 1
P Q D T V S A G	GE	s	v		GN	/ A		$\overline{\tau}$	5 6	K	P (5 D	ĸ	K	K F	· · · · ·	ĸ	s	11A 1	GUU A		GCT	CIG		61 JG	
	%															1	10			~		-	-			
			¢λ	cs	19				+47																	
AAACOGGATAAACCATOGGGAAAC	STCAGG	CAT	GGAT	TGCT	GCTT	TGG	TGA	CTTA	ATAGA	TACT	TTAC	GAG	GACC	TGAA	GAN	CTGA	AGAA	GAA	MT	ACA	ACG	TAT	ACT	GGAC	CAG	;A.4
крркрѕск	130	м	D	*	A 1	. D	D	£.	D	T	1 0	5 G	Ρ	ε	ε 1			E	N	T	T	Y	T	G P	Υ E	1
	1.00								+54	0						1	50									
CAGATOCAATGAGTTOCAOCTAC	CATAGA	NGGA	ATTO	GGGT	~~~	GAG	UGT	CACA			m		GGA	ACTA	TIGO	СТАА		ATA	222		GAT	GAT	GCT	ATAC	acc	*
5 ЭРМ 5 5 ТҮ	Iξ	٤	Ł	G	ĸ	E	۷	T	I P	Ρ	ĸι	r R	Ε	L	٤.	ĸ	2	1 (GI	P	D	D	A	IC) A	Ĩ
	170															1	x									
			-	-					+66	8																•
CATCTGACTTCACCTGTGGGTCC	JOCTAC	AGC	TGCI	GGA	AAGA	, m	TGA	~~~~	SAGGA	ATCT	ACAG	AAG	ΠT	~~~	GCTO	AGTC	AGCA	GGG.	ACA	GTC	AGA	AGTO	GCT	GCTC	CAC	α
SDFTCGS	210	^	^	6		. 1	c	~ 1	: 12	5	1 6	v	L	ĸ	A (ŝ	G	T '	v	R	5,	•	A P	P	2
									+78	0						2.	50									
AGAAGAAAAGAAAGGTGGAGAAA	GATAC	AAT	GAGT	TGAT	CANG	CACT	CGA	GCT	TGTO	GCT	TCAC	TGG	SCAC	COGG	CANG	CAGA	ACCT	GAG	ста	GAO	ста	œc	TCA	ATTA	AGG	
K K R K V E K	DŢ	M	s	D	Q A	L	Ε	A 1	L S		sι	. G	Ŧ	R	Q A	Ε	2	E	. 1	D	LI	RS	5	IΚ	E	
	250															2	70									
ATGAGGCAAAAGCTAAAGAAGAA					00.00		-		+90														_			1
EAKAKEE	K L	E	K	C i	GF	000	D	F 1				AG1/	NCAG D	ATTA		CAGC	-ACG	GAT		GAT	GGA	~~~	CCA	CTAT	TGC	CA
	290	-	.,		• •	•	-	-	•		5		'n		~ ~		8				6 1				۲.	
									+1029	2						-	-									+1
CTGAAGAAAAACCCAAGCCTOGG	AGTGA	ATC	AGAA	ACTC.	ATTG	ATGA	ACT	TICAC	AAGA	m	GACC	GGT	CTGA	ATGT	AAAG	AGAN	ACCA	тсти	VIG	CCA	ACTO	GAN	MG	ACAG		
PEEKPKPR	SĘ	S	ε	L	1 0	E	ι	S E	D	۴	DR	\$	Ε	С	κ ε	к	P :	S · P	K F	•	тε	Ε,	< ·	t E	ε	
	330								+1140							35	50									
AGGCCGCTGCTCCAGCTCCTGTG	TCGGA	GGC.	TGTC	STOT	CGGA	CCTC	CAT	STGT			TCAG	CACC	m	TCAC		CTAC	-		~~~			~~~				+1
	SĘ		۷	S	RT	S	M	C S	1	Q	S A	P	P	E	> A	T	L	ĸ	5 1	T I	VF	, n			v 10	
	370																× -		1						•	
									+126	3						;	١cs	143	ŧ							+1
CCTTOGCTGATAGCCTGGGGAAA	AAGGA	VIGCI	AGAT		GAAG	ATGG		ACCTO	TGAT	GAT	AAAG	CTN	GGA	GAAG	GCCA	AAGA	GAN	GACO	ста	544	AAGO	CTTO	GTO	AAA	AAG	A A
LADSLGK	410	^	U	P (ευ	G	ĸ	P \	м	D	ĸν	ĸ	ε	ĸ	A K			DF	\$ 5	E 1	K 1	. 0	5 8	ĸ	ε	
									+1389	>						43										+1
CAATTOCTOCTGATTATAGATTA	GAAGA	CGT	CAAG	GAT	AAA G	ATGG		CCAC	TCCT	icca	MAG	AGTO	TAN	GGAN	AGC	παс	0000	ATG	GTO	GAN	GACT	пс		TGG	ATG	ст
IPPDYRL	ΕĒ	۷	ĸ	D	K D	G	ĸ	Ρι	. ι	P	ĸε	S	κ	ε (ι	Ρ	P 1	M S	E	E (DF	: L		. D	A	
	450															47	ō									
CTGAGGACTTCTCTGGTCCACAA		πc	ATCT	ictt.		TTGA	AGA1		+1500		CCTO		ore		- + ~ ~	***	~									+1
EDFSGPQ	N A	S	S	LI	KF	E	D	A K	1	A	A A	I	S	F	2 UG	i i u	~~~·							AAG	CTG	3A
	490												ĩ	-		51					, ,			· ^	0	
									+1620																	-16
	GACAAR	AGAC	CTO	GATG	ATG	CTT	GAT	****	TCTCT	GAC	GTCI	TAGG	ACAA	AGGC	ACCO	TGAC	CCAG	ATG	AGA	ACA	**0	CAA	TGG	GAGA		
	0	•		0 0			D	κί	S	υs	ίL	~	0	RC	P	D	2 0	3 (N	K	Р	м	-			1
CACCOOGTGATACCTOGCAGAGT	D K	D	L	DC	•						-	0	•										G	D	ĸ	
CACCOOGTGATACCTOGCAGAGT PRDTSQS	DK	D	L	DC	•				1740		-	0	•			55							G	D		10
AGGAMAAGCTAAAGCTGAACAT/	530	CAAG	сто	D D GGAG		AGAT	IGAC	ACTA	1740	ССТС	AATA	CAG	ACAT	стас	TGGA	55	ō MATG	GAC	NGG.	ACA	AA()	-	FGA		+	TA
NGGAMAAGCTAAAGCTGAACAT/	530 AGAGAC	CAAG	сто	D D GGAG		AGAT	IGAC	ACTA	1740	ССТС	AATA	CAG	ACAT	стас	TGGA	55	ō MATG	GAC	NGG/ D	ACA K	AA Q P	-	FGA		+	TA
AGGAMAAGCTAAAGCTGAACAT/	530	CAAG	сто	D D GGAG		AGAT	IGAC	ACTAT T I	1740 TCCCA	ССТС	AATA	CAG	ACAT	стас	TGGA	55	ō MTG N G	GAC.	NGG/ D	ACA K	AAQ P	-	FGA		+	TA
NGAAMAGCTAAAGCTGAACAT/ EKAKAEHI	530 AGAGAC R D 570	CAAG K		GGAG G E	AAAG R	D	D	ACTAT T I	P 1860	CCTG P E	AATA Y	R R	н	CTCC L L	TGGA D	55 TGAT/ D 1 59	Ö MTG G	Q			P	CAG V	ГGA. К	P	+ ACC P	TA
NGGAMMAGCTAANGCTGAACAT/ EKAKAEHI	AGAGAC R D 570	CAAG K I		GGAG G E CAAG	AAAG R	D	IGAC D		1740 TCCCA P 1860	CCTG P E	AATA	R R	H H		TGGA D	55 TGAT/ D 1 590	Ö MATG V G	Q	~~~~	-	P	V	rga K	P	P P	TA T
NGGAMMAGCTAANGCTGAACAT/ EKAKAEHI	AGAGAC R D 570	CAAG K I		GGAG G E CAAG	AAAG R	D	IGAC D		1740 TCCCA P 1860	CCTG P E	AATA	R R	H H		TGGA D	55 TGAT/ D 590 CACT/ T	Ö NATG G NCAG	Q	~~~~	-	P	V	rga K	P	P P	19
AGGAMMAGCTAMAGCTGAACATA EKAKAEHI NGAAATCAGAGGATTCAAAGAAAG KSEDSKKF	D K 530 AGAGACC R D 570 CCTGCA P A- 610	CAAG K I	CTTO L C	GGAG G E CAAG Q D	AAACCCC	D D CATI	GAC D GAT D	ACTA T I GCTCT A L	+1740 FCCCA P F +1860 FCTCA S 0 +1980	OCTG PE GGAG	AATA Y ATCT	R R IGGA(D	H AGC S	CTCC L L TGTC C P	TGGA D CCTC S	55 TGAT/ D 1 59 59 CACT/ T 5	Ö NATG G NCAG	0 AAAA T	xti s	CAC. Q	P AGAJ N	CAGT V ACAG T	rgaj K Cagi	AGOO P CAAA K	ACC P GGA D	19 17 18
AGGAMMAGCTANAGCTGAACATA E K A K A E H I NJAAATCAGAGGATTCAAAGAAA K S E D S K K F SCAAGAAGGCTGCTTCCAGCTCCA	AGAGAC R D 570 CCTGCA P A- 610	CAAGI K I NGATO D I		GGAG G E CAAG Q D	AAAG R ACCC P		IGAC D GAT D	ACTA TI GCTCT AL	1740 TOCCA P 1860 TCTCA S 0	CCTG CCTG GGAG GGAG GGAG	AATA Y ATCT	R R GGAA D	H AGAGC S	CTCC L L TGTC C P	TGGA D CCTC S	55 TGAT/ D 1 590 CACT/ T 630			S	Q	P AGAJ N	CAGT V ACAG T	rgaj K Cagi	AGOO P CAAA K	ACC P GGA D	19 17 K
NGGAMMAGCTAANGCTGAACAT/ EKAKAEHI	D K 530 AGAGAGAC R D 570 CCTGGAA P A- 610 AAAGGAA K A 1	CAAGI K I NGATO D I		GGAG G E CAAG Q D	AAAG R ACCC P		IGAC D GAT D	ACTA TI GCTCT AL	1740 TOCCA P 1860 TCTCA S 0	CCTG CCTG GGAG GGAG GGAG	AATA Y ATCT	R R GGAA D	H AGAGC S	CTCC L L TGTC C P	TGGA D CCTC S	55 TGAT/ D 1 590 CACT/ T 630			S	Q	P AGAJ N	CAGT V ACAG T	rgaj K Cagi	AGOO P CAAA K	ACC P GGA D	19 17 18
NGAAAAACAAAGCTAAAGCTGAACAT/ EKAKAEHI NGAAATCAGAGGATTCAAAGAAA KSEDSKKF 	AGAGAC R D 570 CCTGCA P A- 610	CAAGI K I NGATO D I		GGAG G E CAAG Q D	AAAG R ACCC P		IGAC D GAT D	ACTAT T I GCTCTAL	1740 P 1 1860 TCTCA S 0 1980 S 1	CCTG CCTG GGAG GGAG GGAG	AATA Y ATCT	R R GGAA D	H AGAGC S	CTCC L L TGTC C P	TGGA D CCTC S	55 TGAT/ D 59 CACT/ T 63 CAAGO K F 670	AATG G ACAG T E		S	Q	P AGAJ N	CAGT V ACAG T	rgaj K Cagi	AGOO P CAAA K	ACC P GGA D	19 17 K
NGAAAAGCTAAAGCTGAACAT/ EKAKAEHI NGAAATCAGAGGATTCAAAGAAA KSEDSKKE XCAAGAAGGCTGCTTCCAGCTCC	D K 530 AGAGAGAC R D 570 CCTGCA 610 AAAGCA K A 1 650	D CAAGI K II NGATO D II NGCTJ	CTTC L C GACC D C	D D GGAG G E CAAG Q D AATGI	AAAAG RAAAG AQQC P GAGG G	AGAT D XATT I I K	IGAC D IGATI D IGCG	ACTAT T I GCTCTAL	1740 FCCCA P 1860 FCTCA S 0 1980 ATTCA S 2100	CCTG P E GGAG G D GCAA	AATA ATCT L AGAC	R R GGAA D XAACJ T	NCAT H CAGC S	CTCC L L TGTC C P GAAA E T	TGGA D CCTC S CTTC S	55 TGAT/ D 59 CACT/ T 63C CAAGC K E 67C 67C	O AATG ACAG T E CAAA	0 AAAG T D	S S TG	CAC Q ACt	P AGAJ N	CAGI V ACAG T	FGA K CAGI A	AGCC P CAAAA K	P GGA D +	T 19 TA 20 20

RIGHTSLINK()

+2190 gascatoctamatattggtttgttattotttccagamagamaatgamttgactggtt

52

HUMAN CALPASTATIN

Nucleotide Sequences of Cloned cDNAs and Primary Structure Deduced for Human Calpastatin

The human calpastatin cDNA was sequenced with the strategy shown in Figure 1. No difference was observed between λ cs 19 and λ cs 143 in the region from 394 to 464 bp in these sequence coordinates. Within the 2314-bp sequence obtained (Figure 2), 31 open reading frames were identified and the longest one, 2019 bp long, was predicted to code for human calpastatin because of its high homology to the nucleotide sequences of pig and rabbit calpastatin. This prediction was confirmed by the following experiment. The longest frame was subcloned in frame into an expression vector and crude extract of *E. coli* cells that produced the expression plasmid was tested for inhibition. The crude extract caused inhibition (Maki, M., *et al.* manuscript in preparation). If human calpastatin is assumed to start from the methionine, which is the same relative position here as in rabbit calpastatin,¹² then human calpastatin consists of 673 amino acids residues with the molecular weight of 72605.1. The clones obtained covered the 5' and 3' untranslated regions, which were 96 bp long and 199 bp long, respectively.

Comparison of the Primary Structure of Human Calpastatin with Those of Pig and Rabbit Calpastatins

Pig and rabbit calpastatins have a domain structure with four internally repetitive sequences (domain 1, 2, 3, and 4) and one non-homologous sequence on the N-terminal region.^{11,12} To find whether human calpastatin also has this structural feature, internal homology was searched. Human calpastatin also had four internally repetitive sequences, each about 140 amino acid residues long (Figure 3a). Human calpastatin was then compared with pig (Figure 3b) and rabbit calpastatins (Figure 3c). The amino acid sequence of human calpastatin was highly homologous with that of pig and rabbit calpastatin, as expected from the nucleotide sequence analysis, but human calpastatin had two deletions in its internal regions. The amino acid sequence of human calpastatin was aligned with the sequences of pig and rabbit calpastatins (Figure 4), allowing deletion, gaps, and insertions to give maximum homology. Human calpastatin had 78% identity (526 identical residues in the 673 residues) and 77% identity (519 identical residues in the 673 residues) to pig and rabbit calpastatins, respectively. One deletion that was 22 amino acid residues long existed in domain L and another that was 13 residues long, in domain 1, according to the definition of the domains' boundary in pig calpastatin.¹¹ This result is summarized in Table I.

DISCUSSION

In the cDNA cloning of human calpastatin, we isolated two clones in addition to λcs 19 and 143. One of these, designated λcs 131, had a high heterogeneity compared to λcs 143. λcs 131 had 10 substitutions of single bases in the region from +87 to 464

FIGURE 2 Nucleotide sequence of cloned cDNA and amino acid sequence deduced for human calpastatin. Nucleotides are numbered as in Figure 1. The amino acid sequence deduced shown beneath is numbered from the N-terminal end of human calpastatin. The coordinates are given above the sequence in base pairs and below in amino acid residues. Dots show exact locations. The 5' boundary of λcs 19 and the 3' boundary of λcs 143 are indicated by arrows.

K. ASADA ET AL.




FIGURE 3 Comparison matrix between human and other calpastatins. Parameters were set so that dots were pointed when 8 residues or more out of 18 matched. a, human to human; b, pig to human; and c, rabbit to human.

by our coordinates that we examined. This suggests that two or more copies of the calpastatin gene may exist in the human genome, if they didn't arise from an error during cDNA cloning or polymorphism of the calpastatin gene in the allele or the individual.

Here, the primary structure of human calpastatin was deduced from the nucleotide sequence of its cDNA and compared with calpastatin from two other mammals. Human calpastatin had around 77% identity to both calpastatins, and retained the consensus sequences proposed by Maki¹⁵ and Emori.¹⁶ These findings suggest that the proposed consensus sequence is essential for the inhibition of calpains.

Human calpastatin had two deletions in domains L and 1, compared to pig and rabbit calpastatins. These deletions were unlikely to be artifacts of the cloning steps, because the deletion in domain 1 was also observed in human calpastatin cDNA derived from the heart as well as the liver (unpublished data). The 34-mer peptide of rabbit calpastatin spanning the residues asp-184 to Gly-217 is the shortest calpastatin fragment so far reported that inhibits both kinds of calpains.¹⁷ The 34-mer peptide of

	Comparis	on to pig calpastatin	Comparison to rabbit calpastatin					
	Position	Number of residues	Position	Number of residues				
Deletions	9–10 189–190	22 13	9–10 189–190	22 13				
Gaps	93–94 222–223 237–238	1 1 1	93-94 219-220 390-391 644-645	1 3 1 1				
Insertions	390–391 494	2 1	16	1				
Number of identical residues		526	519					
Homology		78.2%	77.1%					

RIGHTSLINKA)

TABLE I
Summary of the comparison of sequence alignments between human and other calpastatins




FIGURE 4 Comparison of amino acid sequences of the three calpastatins. Amino acid sequences of human (H), pig (P), and rabbit (R) calpastatins, in this order, are aligned from top to bottom. The coordinates of the amino acid sequence are shown every 50 residues (dotted). The numbers above the sequence refer to human calpastatin and those below refer to the pig and rabbit calpastatins. Gaps (indicated by slashes) were introduced to achieve maximum homology. Residues identical with human calpastatin are marked with dashes. The boundaries of each domain defined for pig calpastatin¹¹ are indicated by vertical arrows above the sequence. The reported "central consensus sequence" in each domain¹⁵ is shaded.

rabbit calpastatin and domain 1 of human calpastatin have 26 residues in common (residues 184 to 209 in rabbit calpastatin and residues 162 to 187 in human calpastatin). By analogy to isolated domain 1 proteins of pig¹⁵ and rabbit¹⁶ calpastatins, it is reasonable to assume that domain 1, alone, of human calpastatin can also exert inhibition of calpains. This would, in turn, imply that the common peptide 26 residues long can still retain inhibitory potency against calpains. The synthesis and test for inhibitory activity of this and related peptides are now in progress.



Acknowledgements

We thank Miss Uchimura for the preparation of the oligonucleotides and Miss Ohara for technical assistance.

References

- 1. Parkes, C. (1986) in *Proteinase Inhibitors* (Barrett, A. J., and Salvesen, G., eds.) pp. 571-587, Elsevier, Amsterdam.
- 2. Murachi, T., Tanaka, K., Hatanaka, M., and Murakami, T. (1981) Adv. Enzyme Regul., 19, 407-424.
- 3. Murachi, T. (1983) Trends Biochem. Sci., 8, 167-169.
- Murachi, T. (1983) in Calcium and Cell Functions (Cheung, Y.W., ed.) vol. 4, pp. 377-410, Academic Press, New York.
- 5. Murachi, T. (1984) Biochem. Soc. Symp., 49, 149-167.
- 6. Pontremoli, S., and Melloni, E. (1986) Annu. Rev. Biochem., 55, 455-481.
- 7. Murray, A.W., Fournier, A., and Hardy, S.J. (1987) Trends Biochem. Sci., 12, 53-54.
- 8. Suzuki, K. (1987) Trends Biochem. Sci., 12, 103-105.
- 9. Mellgren, R.L. (1987) FASEB J., 1, 110-115.
- Takano, E., Maki, M., Hatanaka, M., Mori, H., Zenita, K., Sakihama, T., Kannagi, R., Marti, T., Titani, K., and Murachi, T. (1986) FEBS Lett., 208, 199-202.
- Takano, E., Maki, M., Mori, H., Hatanaka, M., Marti, T., Titani, K., Kannagi, R., Ooi, T., and Murachi, T. (1988) *Biochemistry*, 27, 1964-1972.
- 12. Emori, Y., Kawasaki, H., Imajou, S., Imahori, K., and Suzuki, K. (1987) Proc. Natl. Acad. Sci. USA, 84, 3590-3594.
- Maki, M., Takano, E., Mori, H., Kannagi, R., Murachi, T., and Hatanaka, M. (1987) Biochem. Biophys. Res. Commun., 143, 300-308.
- 14. Maki, M., Takano, E., Mori, H., Sato, A., Murachi, T., and Hatanaka, M. (1987) FEBS Lett., 223, 174-180.
- Maki, M., Takano, E., Osawa, T., Ooi, T., Murachi, T., and Hatanaka, M. (1988) J. Biol. Chem., 263, 10254–10261.
- Emori, Y., Kawasaki, H., Imajoh, S., Minami, Y., and Suzuki, K. (1988) J. Biol. Chem., 263, 2364-2370.
- 17. Emori, Y. (1988) Seikagaku (Tokyo), (mini-review in Japanese) 60, 266-272.
- 18. Gubler, U., and Hoffman, B.J. (1983) Gene, 25, 263-269.
- 19. Hyunh, T.V., Young, R.A., and Davis, R.W. (1985) in DNA Cloning Techniques, A Practical Approach (Glover, D., ed.) vol. 1, pp. 49-78 Oxford, IRL Press.
- 20. Messing, J. (1983) Methods Enzymol., 101, 20-78.

